| 000 | 01113 a2200289 4500 | ||
|---|---|---|---|
| 005 | 20250514162918.0 | ||
| 264 | 0 | _c20040223 | |
| 008 | 200402s 0 0 eng d | ||
| 022 | _a1526-632X | ||
| 024 | 7 |
_a10.1212/01.wnl.0000095425.84407.39 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGoodin, D S | |
| 245 | 0 | 0 |
_aThe use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. _h[electronic resource] |
| 260 |
_bNeurology _cNov 2003 |
||
| 300 |
_a1332-8 p. _bdigital |
||
| 500 | _aPublication Type: Guideline; Journal Article; Practice Guideline; Review | ||
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMitoxantrone _xadverse effects |
| 650 | 0 | 4 |
_aMultiple Sclerosis _xdiagnosis |
| 700 | 1 | _aArnason, B G | |
| 700 | 1 | _aCoyle, P K | |
| 700 | 1 | _aFrohman, E M | |
| 700 | 1 | _aPaty, D W | |
| 773 | 0 |
_tNeurology _gvol. 61 _gno. 10 _gp. 1332-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1212/01.wnl.0000095425.84407.39 _zAvailable from publisher's website |
| 999 |
_c14374036 _d14374036 |
||